Oesophageal cancer: New developments in systemic therapy

Cancer Treatment Reviews

Volumn 29, Issue 6, 2003, Pages 525-532

  Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN; PACLITAXEL; PRINOMASTAT; PROTEIN TYROSINE KINASE; THYMIDYLATE SYNTHASE; TUBULIN;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; SURVIVAL RATE; SYSTEMIC THERAPY; UNITED STATES; WESTERN EUROPE;

EID: 0242475354     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00104-X     Document Type: Article

References (59)

1. Jemal A, Thomas A, Murray T, Samuels A, et al. Cancer statistics. CA J Clin 2003; 53: 5-26.
2. Devesa SS, Blot WJ, Fraumeni Jr JF. Changing patterns in the incidence of oesophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
3. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastrooesophageal reflux as a risk factor for oesophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
4. Koop H. Gastrooesophageal reflux disease and Barrett's oesophagus. Endoscopy 2002; 34: 97-103.
5. Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoma: II. A critical view of radiotherapy. Br J Surg 1980; 67: 457-461.
6. Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77: 845-857.
7. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized oesophageal cancer. N Engl J Med 1998; 339: 1979-1984.
8. Clark P. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomized controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group. Proc ASCO 2001; 20: abstract, 502.
9. Herskovic A, Martz LK, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl J Med 1992; 326: 1593-1598.
10. Leichman L, Herskovic A, Leichman CG, et al. Preooperative therapy for squamous-cell cancer of the oesophagus. J Clin Oncol 1987; 5: 365-370.
11. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the oesophagus: final report. J Clin Oncol 1993; 11: 1118-1123.
12. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
13. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the oesophagus. N Engl J Med 1997; 337: 161-167.
14. Urba SG, Orringer MB, Turrisi A. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional oesophageal carcinoma. J Clin Oncol 2001; 19: 305-313.
15. Ilson D, Arquette M, Costa F et al. Preoperative paclitaxel/cisplatin in oesophageal carcinoma; a phase II multicenter trial. Proc ASCO 1997; 16: abstract, 926.
16. Bains M, Stojadinovic A, Minsky B et al. A phase II trial of preoperative combined modality therapy for localized oesophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002; 124: 270-277.
17. Heath EI, Burtness BA, Heitmiller R, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the oesophagus. J Clin Oncol 2000; 18: 868-876.
18. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in oesophageal cancer. Semin Oncol 1999; 26: 12-20.
19. Bleiberg H, Conroy T, Paillot B, et al. Randomized phase II study of cisplatin and 5-FU versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-1220.
20. Webb A, Cunningham D, Scarffe JH, et al. A randomised trial comparing ECF with FAMTX in advanced oesophago-gastric cancer. J Clin Oncol 1997; 15: 61-267.
21. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
22. Ajani J, Ilson D, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the oesophagus. J Natl Cancer Inst 1994; 86: 1086-1091.
23. Kelsen DP, Ilson D, Wadleigh R et al. A phase II multi-center trial of paclitaxel as a weekly one-hour infusion in advanced oesophageal cancer. Proc ASCO 2000; 19: abstract, 1266.
24. Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93.
25. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the oesophagus. J Clin Oncol 1998; 16: 1826-1834.
26. Garcia-Alfonso P, Guevara S, Lopez P et al. Taxol and cisplatin +5-fluorouracil sequential in advanced oesophageal cancer. Proc ASCO 1998; 17: abstract, 998.
27. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the oesophagus. Cancer J 2000; 6: 316-323.
28. Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998; 78: 511-514.
29. van der Gaast A, Kok TC, Kerkhofs L, et al. Phase II study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 1999; 80: 1052-1057.
30. Philip PS, Gadgeel M, Hussain M et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric and esopahgeal cancers. Proc ASCO 1998; 17: abstract, 1001.
31. Adelstein D, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced oesophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000; 18: 2032-2039.
32. Blanke CD, Choy H, Teng M, et al. Concurrent paclitaxel and thoracic irradiation for locally advanced oesophageal cancer. Semin Radiat Oncol 1999; 9: 43-52.
33. Urba S, Orringer M, Iannettoni M et al. A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy (XRT) before trans-hiatal esophagectomy (THE) in patients (PTS) with loco-regional oesophageal cancer (CA). Proc ASCO 2000; 19: abstract, 960.
34. Kelsen D, Ilson D, Lipton L et al. A phase I trial of radiation therapy plus concurrent fixed dose cisplatin with escalating doses of paclitaxel as a 96 hour continuous infusion in patients with localized oesophageal cancer. Proc ASCO 1999; 18: abstract, 1039.
35. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for oesophageal cancer. Cancer Invest 2001; 19: 1-7.
36. Wright CD, Wain JC, Lynch TJ, et al. Induction therapy for oesophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 1997; 114: 811-815.
37. Meluch AA, Hainsworth JD, Gray JR, et al. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized oesophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999; 5: 84-91.
38. Ajani JA, Komaki R, Walsh GL et al. CPT-11 plus cisplatin as induction chemotherapy followed by chemoradiotherapy in resectable carcinoma of the oesophagus and ge junction. Proc ASCO 2001; 20: abstract, 521.
39. Mauer AM, Haraf DC, Ferguson MK et al. Docetaxel-based combined modality therapy for locally advanced carcinoma of the oesophagus and gastric cardia. Proc ASCO 2000; 19: abstract, 954.
40. Enzinger PC, Kulke MH, Clark JW et al. Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the oesophagus and stomach. Proc ASCO 2000; 19: abstract, 1243.
41. Lin L, Hecht JR. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastrooesophageal (GE) junction. Proc ASCO 2000; 19: abstract, 1130.
42. Blanke CD, Haller DG, Benson Blanke AB et al. Multicenter phase II study of CPT-11, 5-fluorouracil, and leucovorin in patients with previously untreated adenocarcinoma of the stomach or GE junction. Proc ASCO 2000; 19: abstract, 1141.
43. Findlay MPN, Ackland S, Gebski V et al. Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer. Proc ASCO 2001; 20: abstract, 1655.
44. Ilson D, Saltz L, Enzinger P, et al. A phase II trial of weekly irinotecan plus cisplatin in advanced oesophageal cancer. J Clin Oncol 1999; 17: 3270-3275.
45. Ajani JA, Fairweather J, Pisters PW et al. Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinomas. Proc ASCO 1999; 18: abstract, 927.
46. Gold PJ, Carter G, Livingston R. Phase II trial of irinotecan and mitomycin C in the treatment of metastatic oesophageal and gastric cancers. Proc ASCO 2001; 20: abstract, 644.
47. Pozzo C, Bugat R, Peschel C. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastroooesophageal junction adenocarcinoma: final results of a randomised phase II study. Proc ASCO 2001; 20: abstract, 531.
48. Anderson S, Ilson D, Bains M et al. Phase I trial of cisplatin and escalating dose irinotecan given weekly with concurrent radiation in locally advanced oesophageal cancer. Proc ASCO 2001; 20: abstract, 629.
49. Spiridonidis CH, Laufman LR, Jones JJ, et al. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced oesophageal adenocarcinoma. Cancer 1996; 78: 2070-2077.
50. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316.
51. Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumours are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 1282-1293.
52. Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530-542.
53. Raben D, Helfrich B, Chan D et al. Anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Proc ASCO 2001; 20: abstract, 1026.
54. Saltz L, Rubin M, Hochster H et al. Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc ASCO 2001; 20: abstract, 7.
55. Perez-Soler R, Chachoua A, Huberman M et al. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer. Proc ASCO 2001; 20: abstract, 1235.
56. Senzer NN, Soulieres D, Siu L et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc ASCO 2001; 20: abstract, 6.
57. Downey RJ, Ilson D, Koong H et al. 8FDG PET measures the pathologic response of oesophageal cancer to induction therapy. Proc ASCO 2001; 20: abstract, 503.
58. Flamen P, Van Cutsem E, Lerut L et al. The utility of positron emission tomography with 18F-fluorodeoxyglucose to predict the pathologic response and survival of oesophageal cancer after preoperative chemoradiation therapy. Proc ASCO 2001; 20: abstract, 504.
59. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3066.